Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 7/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 2/20 | 0.38 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | NNMT | P40261 | 2/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | HTR1D | P28221 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.33 |
| ▸ | CCNC | P24863 | 1/20 | 0.32 |
| ▸ | CDK8 | P49336 | 1/20 | 0.32 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.32 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31628073 | 0.72 | TSHR (0.49) | OPRM1OPRD1OPRK1CYP2D6KCNH2 | |
| SCHEMBL18153950 | 0.71 | TDP1 (0.41) | OPRM1OPRD1KDM1ATDP1SMYD3 | |
| SCHEMBL17877817 | 0.69 | OPRM1 (0.41) | OPRM1OPRD1OPRK1TSHRKDM1A | |
| SCHEMBL31657080 | 0.67 | KDM1A (0.44) | OPRM1OPRD1OPRK1CYP2D6KCNH2 | |
| SCHEMBL22789664 | 0.67 | KDM1A (0.44) | OPRM1OPRD1OPRK1CYP2D6KCNH2 | |
| SCHEMBL3782343 | 0.66 | COXFA4 (0.49) | CYP2D6KCNH2TSHRKDM1ASIRT2 | |
| SCHEMBL10431871 | 0.66 | HIF1A (0.49) | TDP1 | |
| SCHEMBL4508858 | 0.66 | HDAC3 (0.58) | OPRM1OPRD1OPRK1CYP2D6KCNH2 | |
| SCHEMBL8691132 | 0.65 | TDP1 (0.74) | TSHRTDP1HTR1AHTR1DHTR2C | |
| SCHEMBL15947248 | 0.64 | TSHR (0.43) | OPRM1OPRD1OPRK1TSHRKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9630922-B2 | 3-spiro-7-hydroxamic acid tetralins as HDAC inhibitors | FORMA THERAPEUTICS, INC. (US) | 2017-04-25 | — | — | US | disclosed |
| WO-2016168660-A1 | 3-SPIRO-7-HYDROXAMIC ACID TETRALINS AS HDAC INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2016-10-20 | — | — | WO | disclosed |
| US-20160304462-A1 | 3-SPIRO-7-HYDROXAMIC ACID TETRALINS AS HDAC INHIBITORS | Valo Health, LLC | 2016-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160304462-A1 | 3-SPIRO-7-HYDROXAMIC ACID TETRALINS AS HDAC INHIBITORS | HDAC7, HDAC6, HDAC1 | OPRM1 4852/4885OPRD1 4471/4885OPRK1 4684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.